Home > Clinics and Services > Clinics and Departments > Pediatric Oncology > Experimental Therapeutics in Pediatric Cancer
Pediatric Oncology Experimental Therapeutics in Pediatric Cancer

US News and World Report Ranking Badge

Experimental Therapeutics in Pediatric Cancer


The Experimental Therapeutics in Pediatric Cancer program makes clinical trials available to your child when traditional cancer therapies have not been successful.

We are the only pediatric hospital in the region that provides access to cancer clinical trials, which means your child can benefit from the latest innovations in research while staying close to home. This is important because family connection and familiarity with surroundings has been shown to improve the success of cancer treatment.

What is Experimental Therapeutics?

Our trials test treatment methods that have not yet been used for your child’s diagnosis. Many medications involved in clinical trials have been proven effective and safe for other cancers or for use in adult patients, but not specifically for pediatric cancer. Experimental Therapeutics is the science of taking those treatments and trialing them with different cancers to test their effectiveness.

What are the Phases of a Cancer Research Trial?

Phase 1: A test of a drug to determine its safety and proper dosage for pediatric patients. At this phase, we do not know yet if a drug is effective.

Phase 2: This phase comes after a drug’s safety has been proven and tests the drug’s effectiveness.

Phase 3: This phase ensures a drug meets our standard of care. Phase 3 is designed to verify if a drug can improve on how we currently treat a diagnosis. 

Financial Assistance to Help Fund Your Trial Participation

If your child qualifies for a clinical trial in our program, we provide guidance in finding financial resources to help cover the cost of the trial. In addition to working with Missouri and Kansas Medicaid programs, we also assist with access to Medicaid programs in other states. Many parts of the clinical trial’s process, such as labs, X-rays, and other essentials tests, are covered by your health insurance. 

Our Research Team

The Experimental Therapeutics Research Team works to provide the best in cancer research expertise while providing the emotional support your family needs. Our team includes four doctors, one nurse practitioner, four research coordinators, and one social worker. Learn more about the Hematology, Oncology, and Bone Marrow Transplant team at Children’s Mercy.

Physicians


Jaszianne A Tolbert, MD
Assistant Professor of Pediatrics
Director, Experimental Therapeutics in Pediatric Cancer Program
Division of Hematology/Oncology/Bone Marrow Transplantation
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation

Keith August, MD, MS
Associate Professor of Pediatrics
Director, Leukemia & Lymphoma Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Katherine Chastain, MD
Assistant Professor of Pediatrics
Director, Sarcoma Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Kevin Ginn, MD
Assistant Professor of Pediatrics
Director, Pediatric Brain Tumor Program
Division of Hematology/Oncology/Bone Marrow Transplantation

Nurse Practitioner

Allison Rees, MSN, RN, CPNP-AC
Division of Hematology/Oncology/Bone Marrow Transplantation

Clinical Research Coordinators


Jami Wierson, RN, BSN, MBA, CCRC
Research Coordinator Manager
Division of Hematology/Oncology/Bone Marrow Transplantation

Michelle Dinkins, CCRC
Division of Hematology/Oncology/Bone Marrow Transplantation

Amber Jenkins, MSc, CCRC
Division of Hematology/Oncology/Bone Marrow Transplantation

Chasity Runyan, CCRP
Division of Hematology/Oncology/Bone Marrow Transplantation

Social Work

Caroline Gill, MSW, LMSW, LCSW
Division of Hematology/Oncology/Bone Marrow Transplantation

Investigational Drug Service (IDS) Pharmacy

The Children’s Mercy IDS Pharmacy is a full service pharmacy providing clinical knowledge and operational support for all studies involving investigational drugs at Children’s Mercy. As part of the Experimental Therapeutics Team, the IDS Pharmacy staff provides protocol and sponsor directed security, accountability, education, and dispensing of all Investigational as well as ancillary medications.

Cancer Trials Currently Available

Treatment Area Study Name
Relapsed/Refractory Leukemia (B-ALL) A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Relapsed Leukemia (AML)  A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
Refractory Solid Tumors A Phase 2 Study of Pazopanib in Children, Adolescents, and Young Adults with Refractory Solid Tumors 
Relapsed/Refractory Solid Tumors or Lymphoma  A Phase 1/2 Study of Pembrolizumab in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma 
Refractory Solid Tumors  A Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Relapsed Osteosarcoma  A Phase 2 Study of Human-Mouse Chimeric Disialoganglioside Monoclonal Antibody ch 14.18 (Dinutuximab) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma 
Relapsed/Refractory Neuroblastoma or Medulloblastoma   A Phase 2 Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
Relapsed/Refractory Solid Tumors or CNS tumors  Molecular-guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers  
Relapsed/Refractory Neuroblastoma  A Phase 1/2 Trial of DFMO in Combination with Bortezomib in Patients with Relapsed or Refractory Neuroblastoma  
Neuroblastoma in Remission Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO) 
Relapsed/Refractory Solid Tumors or CNS tumors  Relapsed/Refractory Solid Tumors or CNS tumors A Phase 2 Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Relapsed/Refractory Leukemia (AML)  A Phase 1 Study of Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia 
Relapsed/Refractory Solid Tumors  A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors 

 

Copyright © 2017 The Children’s Mercy Hospital